Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universita Degli Studi Di Roma Tor Vergata |
| Country | Italy |
| Start Date | Jan 01, 2021 |
| End Date | Jun 30, 2025 |
| Duration | 1,641 days |
| Number of Grantees | 24 |
| Roles | Coordinator; Participant; Third Party |
| Data Source | European Commission |
| Grant ID | 101017453 |
AI-empowered Personalized Medicine promises to find tailored, targeted, nearly hand-made cures for patients.
Cancer treatment desperately needs boosters to find tailored, targeted cures for patients and Personalized Medicine can play a crucial role.
Tailored targeted therapies in cancer treatment are already a reality but the current practice of targeted therapies in cancer treatment has been derived with traditional methods of data analysis. AI-empowered Personalized Medicine may help to bring targeted therapies to the next level.
However, no matter how precise it is, no matter how many lives it can save in principle, and no matter if it can utilize the entire medical knowledge.
If clinicians do not understand its suggestions and decisions, AI-empowered Personalized Medicine will not be a game changer, clinicians will not use it to make everyday decisions and, thus, it is doomed to fail.
Hence, the real challenge is building AI-empowered Personalized Medicine systems that can be accepted by clinicians and clinical researchers.
In KATY, we grasp the above challenge and we propose an AI-empowered Personalized Medicine system that can bring medical AI-empowered knowledge to the tips of the fingers of clinicians and clinical researchers.
The AI-empowered knowledge is a human interpretable knowledge that clinicians and clinical researchers can: understand, trust and effectively use in their everyday working routine.
KATY is then a AI-empowered Personalized Medicine system built around two main components: A Distributed Knowledge Graph and A pool of eXplainable Artificial Intelligence predictors.
As a stress test and due to the lack of personalized clinical responses, KATY will be experimented in a low prevalence and complex cancer: Clear cell renal cell carcinoma (ccRCC).
Universita Degli Studi Di Roma Tor Vergata; Fciencias.Id - Associacao Para A Investigacao E Desenvolvimento de Ciencias; Institouto Politikis Ygeias Astiki Mi Kerdoskopiki Etaireia; Lunds Universitet; Personal Genomics Srl; Universidad de Zaragoza; Ethniko Kai Kapodistriako Panepistimio Athinon; Universitat Wien; Commissariat A L Energie Atomique Et Aux Energies Alternatives; Eurice European Research and Project Office Gmbh; Ds Tech Srl; Caretronic Razvoj in Proizvodnja Naprednih Informacijskih Resitev D.O.O.; The University Court of the University of St Andrews; Lab4Life Spolka Z Ograniczona Odpowiedzialnoscia; Lothian Health Board; Uniwersytet Gdanski; National Technical University of Ukraine Igor Sikorsky Kyiv Polytechnic Institute; Centre Hospitalier Universitaire de Grenoble; Faculdade de Ciencias Da Universidade de Lisboa; Open Evidence; Fundacio Eurecat; Predictby Research and Consulting S.L.; Fondazione Irccs Istituto Nazionale Dei Tumori; The University of Edinburgh
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant